ArchiveOverlap syndrome (OVS) is a coexisting disease of chronic obstructive pulmonary disease and sleep-disordered breathing, which is related to poor prognosis and increased mortality. In 2017, the American Thoracic Society issued an official statement on the main issues in the pathophysiology of OVS. The purpose of this statement is to clarify the progress of the pathophysiology, epidemiology, prognosis, diagnostic criteria, and treatment of OVS, and to identify important issues that need to be addressed, and to provide recommendations and guidance. This paper will interpret this statement and provide reference for the clinical diagnosis and treatment of OVS in China.
Obstructive sleep apnea syndrome (OSA) is a sleep apnea disease, mainly manifested as apnea, snoring and daytime sleepiness during sleep, which seriously affects the quality of life of patients. In recent years, more and more evidence has shown that orofacial myofunctional therapy can significantly improve snoring, daytime sleepiness, apnea and hypoxia, improve OSA patients' quality of life. This review summarized the concept, mechanism and efficacy of orofacial myofunctional therapy, to provide reference for the clinical work.
Obstructive sleep apnea hypopnea syndrome (OSAHS) is a common sleep disordered breathing disease. Its pathogenesis is related to the abnormal anatomical results of the upper respiratory tract and sleep-related the weakening of the muscle function of the upper respiratory tract. In recent years, with the progress of medical science and technology and the in-depth study of relevant mechanisms, some previous clinical studies on the second-line treatment of upper respiratory muscles show the optimistic treatpeutic prospect, which may become an important method of OSAHS treatment and bring new hope and major breakthroughs for the treatment of OSAHS in the future. Therefore, this article reviewed treatments in the above fields.
To study the effects of astragalus polysaccharide (APS) on islet function and serum glucagon-like peptide-1 (GLP-1) level in diabetes mellitus (DM) rats.
Twenty Wister rats were randomly divided into model group (normal saline) and astragalus polysaccharide group, with ten rats in each group. The DM rat model was established by intraperitoneal injection of streptozotocin combined with high-fat diet, and ten Wistar rats were set as the normal group. After intragastric administration for eight weeks, the insulin secretion in the early phase and the second phase was evaluated, the insulin resistance index and sensitivity index were calculated, the changes of pancreatic tissue were observed, and the level of GLP-1 was measured.
After glucose load, the peak of blood glucose in the model group was delayed and reached the peak at sixty minutes. The blood glucose in the model group increased the most, and the blood glucose in the APS group decreased significantly after intervention (P<0.01). In the normal group, the rapid insulin secretion reached the peak 15 minutes after glucose load, the insulin secretion in the model group was gentle, while the peak insulin secretion peaked at thirty minutes in the APS group. In the model group, the area under ROC curve120 insulin, insulin production index15, insulin production index120 and insulin sensitivity index of steady-state mode evaluation method were significantly lower than those in the normal group (P<0.01), and APS increased significantly after intervention (P<0.01). The prognosis of APS group was significantly higher than that of normal model group (P<0.05). The normal group had more islet cells, plump granules, complete islet morphology and clear boundary. In the model group, the islet cells were severely damaged, the number decreased, the granules lost, the islets became smaller and the number decreased, showing amyloidosis, irregular morphological edges and obvious atrophy. In the APS group, there were more islet cells with complete morphology, but the islets became smaller and changed in morphology.
APS can significantly increase the level of GLP-1 at each time point, improve the islet dysfunction of DM rats, reduce glucose tolerance and insulin resistance, improve early insulin secretion, insulin sensitivity and GLP-1 level, and regulate blood glucose.
To observe the therapeutic effect and safety of Longkui Yinxiao tablets combined with acitretin A capsules on moderate to severe psoriasis vulgaris with blood heat syndrome.
A total of 134 moderate to severe psoriasis vulgaris patients with blood heat syndrome were randomly divided into treatment group (n=67) and control group (n=67). The treatment group was treated with Longkui Yinxiao tablets combined with acitretin A capsales, and the control group was treated with the acitretin A capsules. Both groups were treated with allantoin vita cream. The course of treatment was 12 weeks. Clinical efficacy, psoriasis area and severity index (PASI), visual analogue scale (VAS), dermatology life quality index (DLQI), Hamilton depression scale (HAMD) and the incidence of adverse reactions were compared between the two groups.
Finally, 130 patients were concluded in this study, 66 cases in the treatment group and 64 cases in the control group. The effective rate in the treatment group (87.50%) was higher than that in the control group (70.00%)(P<0.05). The scores of PASI, VAS, DLQI and HAMD in the two groups after treatment were all significantly lower than those before treatment (P<0.05). The treatment group was superior to the control group in improving of PASI and pruritus (P<0.05). While, there was no significant difference in DLQI and HAMD between the two groups (P>0.05). The incidence of dry mouth in the treatment group was 4.55%, which was significantly lower than 18.75% in the control group of (P<0.05). There was no significant difference in the incidence of eye dryness, hyperlipidemia and paronychia between the two groups (P>0.05).
Longkui Yinxiao tablets combined with acitretin A capsules can improve the clinical efficacy of acitretin A capsules alone in the treatment of moderate to severe psoriasis vulgaris with blood heat syndrome, reduce the adverse reactions of acitretin A capsules and better improve the pruritus symptoms, which is worthy of clinical promotion and application.
In order to compare the effectiveness of clopidogrel and ticagrelor in platelet ihibition in patients with acute coronary syndrome (ACS) undergoing stent implantation, and to evaluate the clinical benefits and risks.
Two hundred patients with ACS undergoing stent implantation from June 2016 to December 2019 were enrolled and randomly divided into clopidogrel group and ticagrelor group in Ruijin Hospital, and 100 cases in each group. Adenosine diphosphate (ADP) inhibition ratio, maximum amplitude adenosine diphosphate (MAADP) and arachidonic acid (AA) inhibition ratio were tested with thromboelastogram (TEG) within three days after stent implantation, as well as adverse cardiovascular events and bleeding complications were followed up and observed within one year after stent implantation.
ADP inhibition ratio in ticagrelor group was higher than that in clopidogrel group (P<0.05), MAADP in ticagrelor group was lower than that in clopidogrel group (P<0.05). There was no significant difference of AA inhibition ratio, adverse cardiovascular events and bleeding events between two groups (P>0.05).
Ticagrelor was more effective than clopidogrel on platelet inhibition, but their clinical efficacy and safty were similar.
To observe the clinical effects of comprehensive therapy of traditional Chinese medicine (TCM) on the patients with diabetes mellitus (DM) in the early stage.
A prospective randomized controlled study design was adopted. According to the neighborhood committee of the intervention object, the group was randomly divided into treatment group (n=201, routine lifestyle education+comprehensive therapy of TCM) and control group (n=167, routine lifestyle education). All patients were intervened for one year. The prognosis and changes of glucose and lipid metabolism indexes in the two groups in the early stage of DM were observed.
After one year of follow-up, 189 cases in the treatment group (12 cases lost follow-up) and 157 cases in the control group (10 cases lost follow-up) completed the follow-up. In the treatment group, 80 cases (42.33%) were converted to normal glucose tolerance and 10 cases (5.29%) were converted to DM. In the control group, 57 cases (36.31%) were converted to normal glucose tolerance and 22 cases (14.01%) were converted to DM (P<0.05). After the intervention, the fasting blood glucose (FBG) and 2-hour postprandial blood glucose (2hPG) in the treatment group decreased (P<0.05). In the control group, 2hPG decreased (P<0.05). Compared with the control group, the difference of FBG and triacylglycerol in the treatment group was statistically significant (P<0.05).
The comprehensive therapy of TCM can reduce the risk of DM in the early stage of DM in the community.
To study the clinical effect and mechanism of Guifu Dihuang pills combined with losartan potassium in treating diabetic nephropathy (DN) with Yang deficiency and blood stasis.
The clinical data of 104 patients with stage Ⅲ DN diagnosed in the department of geriatrics of Shanghai baoshan hospital of integrated traditional Chinese and western medicine (TCM) from June 2018 to December 2019 were collected. They were given basic treatment and were randomly divided into western medicine group (n=33, losartan potassium treatment), TCM group (n=35, Guifu Dihuang pills treatment) and TCM and western medicine group (n=35, Guifu Dihuang pills+losartan potassium treatment). The course of treatment was 3 months. The changes of TCM syndrome efficacy, clinical efficacy, urinary microalbumin (mALB), serum creatinine (Scr), blood urea nitrogen (BUN), angiotensin Ⅱ (Ang Ⅱ), serum cystatin C (Cys-C) and homocysteine (Hcy) were compared before and after treatment.
The effective rate of TCM syndrome in TCM group (85.71%) and TCM and western medicine group (88.88%) was better than that in western medicine group (18.18%)(P<0.05). There was no significant difference in clinical efficacy between TCM and western medicine group (77.78%), western medicine group (69.70%) and TCM group (65.72%) (P>0.05). Scr, BUN and mALB in the three groups decreased after treatment (P<0.05), and the improvement of TCM and western medicine group was better than that of western medicine group and TCM group (P<0.05). The levels of Ang Ⅱ, Cys-C and Hcy in the three groups decreased after treatment (P<0.05), and the levels of Ang -Ⅱ, Cys-C and Hcy in the TCM and western medicine group were lower than those in the western medicine group (P<0.05).
Guifu Dihuang pills combined with losartan potassium is effective in the treatment of stage Ⅲ DN of Yang deficiency and blood stasis type, which is worthy of clinical application and popularization.
To observe the effects of 0.1% sodium hyaluronate eye drops on the corneal sensitivity after long-term orthokeratology in myopic children and adolescents.
Myopic children and adolescents aged 8~16 years who wear orthokeratology lens in our hospital from January 2016 to December 2016 were included. The patients were randomly divided into the control group (n=32, orthokeratology lubricant) and the observation group (n=30, 0.1% sodium hyaluronate eye drops). The right eyes of patients were taken as the experimental eyes. Cochet-Bonnet keratometer was used to examine the central, inferior, superior, nasal and temporal corneal sensitivity before and after one-year wearing of orthokeratology in the two groups. The course of treatment was one year.
After one year of wearing orthokeratology, the central, inferior and nasal corneal sensitivity were lower than those before wearing the lens (P<0.05), while the superior and temporal corneal sensitivity had no statistically difference with those before wearing the lens (P>0.05) in the control group. In the observation group, the central, inferior, superior, nasal and temporal corneal sensitivity had no statistically difference with those before wearing the lens (P>0.05). After one year of wearing orthokeratology, there were statistically difference in the central and inferior corneal sensitivity between the two groups (P<0.05).
Long-term wearing of orthokeratology lens can cause the decrease of corneal sensitivity. 0.1% sodium hyaluronate eye drops can help protect the corneal sensitivity after long-term orthokeratology in myopic children and adolescents.
To investigate the efficacy and safety of calcium polycarbophil on constipation during pregnancy.
A total of 260 pregnant women with constipation were randomly divided into the observation group (130 cases) and the control group (130 cases). The control group was treated with basic treatment (clinical care, psychological counseling and dietary intervention) with testa triticum tricum purif (3.5 g every time, 3 times a day, orally), combined the observation group was given calcium polycarbophil tablets (1 g every time, 3 times a day, orally) with basic treatment. The course of treatment is 14 days. Bristol score was used to record the frequency of defecations, the improvement of hemorrhoids and anal fissure, evaluate the severity of constipation and therapeutic effect.
After 14 days of treatment, the total effective rate in the observation group and the control group was 92.31% and 68.46% respectively, and the difference was statistically significant (P<0.05). The effective rate of anal fissure and hemorrhoids relief in the observation group and the control group was 53.8% and 31.9% respectively, with statistical significance (P<0.05). The incidence of adverse reactions in the observed and control groups was 6.92% and 4.62%, respectively, and there was no significant difference between the two groups (P>0.05). In addition, 2 weeks after the termination of treatment, the recurrence rate in the observed group was 7.69%, which was significantly lower than that in the control group (36.15%), the difference was statistically significant (P<0.05).
Calcium polycarbophil can effectively and safely improve constipation during pregnancy.
To explore the clinical effects of aescin combined with ceftriaxone in the treatment of bacterial meningitis (BM).
A prospective study was conducted on 80 patients with BM admitted to Ningguo people's hospital from April 2019 to April 2021. According to the random lottery method, they were divided into observation group and control group at a ratio of 1∶1, with 40 cases in each group. The control group was treated with ceftriaxone, and the observation group was treated with aescin combined with ceftriaxone. We would compare the efficacy, time of symptom disappearance, inflammatory factors before and after treatment [procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP), soluble vascular cell adhesion molecule 1 (sVCAM-1)], oxidative stress indicators [superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA)], brain edema index [aquaporin 4 (AQP4), S-100 calcium binding protein (S-100B)] and treatment the incidence of adverse reactions during the period.
The total effective rate of the observation group was 92.50%, higher than that of the control group 75.00% (P<0.05). The observation group had less time of fever resolution, disappearance of intracranial hypertension, recovery of consciousness, and the disappearance of convulsions were shorter time than those in the control group (P<0.05). The levels of serum PCT, IL-6, CRP, sVCAM-1, AQP4, and S-100B in the observation group were lower than those of the control group (P<0.05). After treatment, the serum SOD and GSH-Px levels in the observation group were higher than those in the control group, and the MDA level was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Aescin combined with ceftriaxone has a significant effect in the treatment of BM patients, which can effectively promote the improvement of symptoms, reduce inflammation and oxidative stress in the body, relieve cerebral edema with high safety.
To investigate the effects and risk factors of ceftazidime/avibactam (CAZ/AVI) in the treatment of carbapenem-resistant Klebsiella pneumonia (CRKP) infection in patients after liver transplantation, and it can provide reference for anti-infection treatment.
All 20 cases with CRKP infection treated by CAZ/AVI after liver transplantation in Beijing Youan hospital from October 2020 to September 2021 were retrospectively analyzed infection indexes, liver and kidney function indexes were compared before and after treatment. Pathogenic bacteria, treatment plan and course, outcome and risk factors were assessed.
After liver transplantation, CRKP were detected in 8 cases, mixed infection were detected in 12 cases, among which CRKP was detected in 6 donor preservation fluids. The treatment time was (10.60±7.36) d. All 4 cases were treated with single drug (CAZ/AVI) and 16 cases were treated with combination therapy. The effective rate was 75%. After treatment, the infection indexes in the effective group were those in the ineffective group. Glutaminotransferase, total bilirubin, direct bilirubin in the effective group were lower than those in the ineffective group. Continuous renal replacement therapy (CRRT) was the risk factor for the treatment failure with CAZ/AVI.
CAZ/AVI can be used as a candidate choice for CRKP infection after liver transplantation, and CRRT contribute to the treatment failure.
According to analysis on the basic characteristics of listed innovative drug, market access and medical insurance access from 2017 to 2020 in China, we provided a reference for the early layout of the follow-up market and medical insurance decision-making.
The chemical innovative drugs and biological drugs listed in China from 2017 to 2020 were selected as the research object, and the differences in drug types, production attributes and evaluation items were analyzed from the aspects of overall situation, disease field and medical insurance access.
The number of listed drugs increased steadily in the past four years. Among them, the number of chemical drugs was significantly higher than that of biological drugs, the number of imported drugs was significantly higher than that of domestic drugs, and the number of listed drugs, drugs entering the medical insurance catalogue and innovation review projects in the field of cancer were the largest.
In the future, chemical drugs will still occupy the dominant position in the market. Biopharmaceutical technology and domestic innovation ability need to be further improved. In popular areas such as oncology, drugs are more innovative and the access rate of drug medical insurance is also high.
To evaluate the long-term cost-effectiveness of pioglitazone-metformin versus sitagliptin-metformin in treating Chinese type 2 diabetes mellitus (T2DM) patients, in order to provide reference for rational drug use in clinic.
From the health system perspective, we simulated the quality-adjusted life years (QALYs) of patients over 30 years using the validated CORE diabetes model. Inputs of baseline risk factors were extracted from Chinese epidemiological studies, clinical efficacy and medication cost data were obtained from relevant published resources in China, utility data are model default values. Both outcomes and costs were discounted at 5% annually. In this paper, one-way sensitivity analyses were conducted for discount rates and study durations. Monte Carlo simulation was used for probability sensitivity analysis, and scenario analysis was done for a treatment algorithm without second-line therapy.
Basic case analysis indicated that, compared with the sitagliptin-metformin regimen, pioglitazone-metformin regimen lowered the incidence of complication, increased cumulative QALYs by 0.02 (9.49 QALYs vs 9.47 QALYs), and reduced total cost by 7 804 yuan (298 214 yuan vs 306 018 yuan). It was an absolute economic advantage scheme and robust sensitivity analysis results.
In the long-term health economic context, compared with sitagliptin-metformin, pioglitazone- metformin is a more economical treatment option with improved QALYs and reduced direct medical costs among Chinese T2DM patients.
In recent years, flood disasters occur frequently in China. The flood disaster pharmaceutical care emergency support system needs to be developed and improved urgently, so as to effectively ensure the safety of people's lives. This paper reviewed the present situation of the emergency medicines, reserve and pharmaceutical care emergency system in China, and analyzed the characteristics of American pharmaceutical care emergency system from the responsibilities of emergency medicine management organization and forms of national reserves of emergency drugs, so as to provide the reference for the development of actual pharmaceutical emergency guarantee in China.
Chimeric antigen receptor T-cell (CAR-T) therapy, as an innovative therapy, has high clinical value, but its high treatment cost and uncertainty of long-term efficacy bring challenges to medical insurance access. This paper explored the design framework and key elements of CAR-T therapy risk sharing protocol by combing international experience and Chinese practice characteristics, in order to provide reference for Chinese health insurance access policy.
Lung cancer is one of the most common malignant tumors in the world, and it is also the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) is the main type of lung cancer, and epidermal growth factor receptor (EGFR) gene mutation is a common driving gene for NSCLC. The first and second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in the treatment of NSCLC with EGFR mutation-positive, but they are prone to drug resistance caused by T790M mutation. Almonertinib is a noval and irreversible third generation EGFR-TKI independently developed in China. It has high selectivity to EGFR sensitization and T790M drug resistance mutation and also has good central nervous system activity and tolerance. In this paper, we reviewed the mechanism of action, pharmacodynamics, pharmacokinetics, clinical research and combination therapy of almonertinib, to provide a reference for clinical application.
Chemotherapy-induced nausea and vomiting (CINV) in cancer patients is common in clinical practice. Traditional Chinese medicine (TCM) has a significant effect on relieving CINV in cancer patients. Based on the special constitution of people in high altitude areas mainly consists of Qi deficiency, phlegm dampness, blood stasis and Qi stagnation. It is proposed that the pathogenesis of CINV in high altitude areas is closely related to the lung, spleen and kidney. The pathogenesis is characterized by Qi deficiency of lung, spleen and kidney, Yang deficiency and blood stasis, accumulation of damp and heat. It is often treated according to the principles of nourishing Qi, warming Yang, removing dampness and promoting blood circulation. In addition, the importance, necessity and the characteristics of medication of the application of invigorating Qi and promoting blood circulation, warming Yang and dampness in CINV for cancer patients in high altitude areas were also analyzed. This paper can provide some clinical reference for TCM treatment of CINV in cancer patients in high-altitude tumor patients.
Interleukin (IL)-17, includes six subtypes such as IL-17A and IL-17F, plays an important role in the pathogenesis of a variety of immune-mediated diseases. The currently marketed IL-17A inhibitors have good effects on psoriasis, psoriatic arthritis and ankylosing spondylitis. Bimekizumab (UCB4940) is a noval humanized monoclonal immunoglobulin G1 antibody developed by Belgium's Utimes Company, which is designed to selectively bind to specific sites on IL-17A and IL-17F, and simultaneously inhibiting both IL-17A and IL17F, thereby producing a stronger anti-inflammatory effect than inhibiting IL-17A alone. The latest phase Ⅲ clinical study data show that bimekizumab is effective in treating psoriasis and is well tolerated. This article reviewed the pharmacology, pharmacokinetics, clinical efficacy evaluation and safety of bimekizumab.